Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROGEL vs ISOVUE-300
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Primary hypogonadism (congenital or acquired),Hypogonadotropic hypogonadism,Off-label: delayed puberty in males, certain breast cancers
Intravascular administration for radiography (e.g., angiography, urography),Intrathecal administration for myelography,Intracavitary administration for arthrography, hysterosalpingography, etc.
50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.
Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.
The terminal elimination half-life of testosterone from Andro Gel is approximately 10-12 hours when applied topically, but due to continuous absorption from the skin depot, serum levels are sustained over 24 hours, allowing once-daily dosing.
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 m L/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Hepatic via CYP3A4, CYP2C9, and 17β-hydroxysteroid dehydrogenase; metabolites include estradiol and dihydrotestosterone.
Not metabolized; excreted unchanged by glomerular filtration.
Approximately 90% of a topical dose is excreted in urine as conjugated and unconjugated metabolites, with about 6% excreted in feces via bile; renal elimination is the primary route.
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Approximately 98% of circulating testosterone is protein-bound: 40-50% bound to sex hormone-binding globulin (SHBG) and 50-60% loosely bound to albumin.
Iopamidol (active ingredient) is minimally protein bound (<5%), primarily to albumin.
The apparent volume of distribution of testosterone is about 1.0 L/kg, reflecting extensive distribution into tissues, particularly muscle, skin, and male reproductive organs.
Approximately 0.20–0.30 L/kg, indicating distribution primarily within extracellular fluid space; low tissue binding.
Bioavailability of testosterone from Andro Gel is approximately 10-14% of the applied dose, due to limited skin permeation and first-pass metabolism (though minimal with transdermal route). For comparison, oral testosterone bioavailability is <1%, while intramuscular testosterone enanthate has 100% bioavailability.
Not applicable for oral route as it is used only intravascularly or intrathecally; bioavailability is 100% for IV injection and near 100% for intra-arterial and intrathecal administration.
No specific dose adjustment is provided for renal impairment. Use with caution in patients with severe renal impairment due to potential for fluid retention.
GFR <30 m L/min: Use with caution; consider lower dose and ensure adequate hydration. GFR <15 m L/min: Avoid use unless essential; post-procedure hemodialysis may be considered. No specific dose reduction formula; clinical judgment advised.
Contraindicated in patients with Child-Pugh class C (severe hepatic impairment). Use with caution and monitor liver function in mild to moderate hepatic impairment; no specific dose reduction guidelines exist.
No specific Child-Pugh based dose adjustments; use cautiously in severe hepatic impairment due to altered pharmacokinetics.
Not indicated in pediatric patients under 18 years of age; safety and efficacy have not been established.
Weight-based: 1-2 m L/kg (300 mg iodine/m L) intravenously; maximum total dose 300 mg iodine/kg. Adjust for body habitus and procedure.
Elderly patients may be more sensitive to androgens, and require careful monitoring for prostate enlargement, prostate cancer, and fluid retention. Start at the lowest dose (25 mg daily) and titrate based on serum testosterone levels and clinical response.
Elderly patients may have reduced renal function; assess GFR and adjust dose accordingly. Ensure adequate hydration before and after procedure. Monitor for nephrotoxicity and hypersensitivity.
None.
No FDA boxed warning.
Risk of secondary exposure to testosterone (children) – avoid skin contact,Polycythemia (monitor hematocrit),Prostate enlargement/cancer risk,Cardiovascular risk (especially in elderly),Spermatogenesis suppression,Hepatic effects (monitor liver function),Edema (in patients with preexisting conditions)
Risk of serious hypersensitivity reactions (including anaphylaxis),Acute kidney injury in patients with pre-existing renal impairment or other risk factors,Thyroid dysfunction (especially in neonates) due to iodine load,Pregnancy and lactation considerations
Known hypersensitivity to testosterone or gel components,Prostate cancer,Breast cancer (males),Women who are pregnant or may become pregnant (risk to fetus)
Known hypersensitivity to iopamidol or any components of the formulation,History of severe adverse reaction to iodinated contrast agents
No specific food interactions. Grapefruit juice may increase testosterone levels due to CYP3A4 inhibition, but clinical significance is unclear. Avoid excessive alcohol intake as it may affect testosterone levels and liver function.
No specific food interactions. However, patients are typically advised to avoid solid food for a few hours before the procedure (e.g., 4-6 hours NPO prior to injection) to reduce the risk of aspiration if emesis occurs. Also, ensure adequate hydration: recommend clear liquids (water, juice) unless contraindicated (e.g., pre-procedure fasting for other reasons).
Andro Gel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus abnormalities) when exposed during the first trimester. Second and third trimester exposure may cause pseudohermaphroditism in females. Risk is highest during the first 12 weeks of gestation.
Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second/third trimester: Risk of transient neonatal hypothyroidism if high doses used; fetal goiter reported. No teratogenic effects at clinical doses in animal studies.
Testosterone is excreted into breast milk with an estimated M/P ratio of 0.1-0.3. It may cause virilization in nursing infants. Breastfeeding is not recommended during Andro Gel therapy.
Iopamidol is excreted into breast milk in small amounts (<1% of maternal dose). M/P ratio not established. Discontinue breastfeeding for 12-24 hours after administration, or pump and discard. Use only if clearly needed.
Andro Gel is contraindicated in pregnancy; no dose adjustments are applicable. If exposure occurs, discontinue immediately and monitor for fetal effects.
No specific dose adjustments for pregnancy; use lowest effective dose. Increased plasma volume may slightly dilute contrast, but no dose change recommended. Avoid in patients with impaired renal function or hyperthyroidism.
Apply to clean, dry, intact skin on shoulders, upper arms, or abdomen. Avoid application to genitals or chest due to higher absorption and risk of transfer. Wash hands after application. Allow gel to dry before dressing. Monitor serum testosterone, hematocrit, PSA, and lipid profile. Contraindicated in men with breast or prostate cancer. May cause erythrocytosis, sleep apnea, or worsening of BPH. Risk of testosterone transfer to women or children; cover application site or wash skin before contact.
ISOVUE-300 (iopamidol) is a nonionic, low-osmolality iodinated contrast medium used for intravascular and intrathecal administration. Key pearls: 1) Pre-hydrate patients with normal saline to reduce risk of contrast-induced nephropathy, especially in those with e GFR <30 m L/min/1.73m². 2) Screen for prior allergic-like reactions; consider premedication with corticosteroids (e.g., prednisone 50 mg PO q12h for 3 doses prior) and antihistamines (diphenhydramine 50 mg IV/PO 1 hour before) for history of moderate or severe reactions. 3) Avoid intrathecal use if there is suspicion of elevated intracranial pressure or CSF obstruction. 4) Metformin should be held for 48 hours post-procedure and only resumed after renal function recheck. 5) Have emergency equipment (oxygen, epinephrine, IV access) readily available for treatment of anaphylactoid reactions.
Apply Andro Gel once daily at the same time each morning to clean, dry, intact skin on shoulders, upper arms, or abdomen.,Do not apply to genitals or chest.,Wash hands thoroughly with soap and water after application.,Allow gel to dry completely before dressing or coming into contact with others.,Avoid swimming, showering, or bathing for at least 5 hours after application.,If skin contact with another person is likely, cover the application site with clothing or wash the area before contact.,Keep Andro Gel away from children and women of childbearing potential.,Report any signs of deep vein thrombosis (leg swelling, pain, warmth), heart attack (chest pain, shortness of breath), or stroke (sudden weakness, confusion, vision changes).,Regular blood tests are required to monitor testosterone levels, red blood cell count, prostate health, and cholesterol.,Andro Gel may interact with blood thinners (e.g., warfarin) and corticosteroids; inform all healthcare providers.
This contrast agent may cause a warm sensation or metallic taste during injection; these sensations are temporary.,Notify the technologist immediately if you experience itching, hives, difficulty breathing, or swelling of the face or throat.,You should drink plenty of fluids (water) before and after the procedure to help clear the contrast from your kidneys unless otherwise instructed.,If you take metformin for diabetes, you may need to stop it for 48 hours after the procedure; your doctor will advise when to restart.,Inform your healthcare provider about any allergies (especially to iodine or contrast media), kidney problems, asthma, or if you are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROGEL vs ISOVUE-300, answered by our medical review team.
ANDROGEL is a Androgen that works by Androgen receptor agonist; testosterone replacement therapy to restore serum testosterone to physiologic levels.. ISOVUE-300 is a Contrast Media that works by Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROGEL and ISOVUE-300 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROGEL is: 50 mg (5 g gel) applied topically once daily, preferably in the morning. Dose may be adjusted between 25 mg (2.5 g gel) and 100 mg (10 g gel) based on serum testosterone levels.. The standard adult dose of ISOVUE-300 is: Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROGEL and ISOVUE-300 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROGEL is classified as Category C. AndroGel (testosterone) is contraindicated in pregnancy. Testosterone is a teratogen with masculinization of female fetuses (clitoral enlargement, labial fusion, urogenital sinus a. ISOVUE-300 is classified as Category C. Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.